IP Library Assignment 051106/0677
Patent Assignment
Reel/Frame 051106/0677

Termination of Patent and Trademark Security Agreement

Recorded: 2019-11-25 Pages: 14
Assignor
Assignee
KADMON CORPORATION, LLC
450 EAST 29TH STREET, NEW YORK, NEW YORK, 10016
Covered Properties (54)
Inhibitors of Mtor Kinase as Anti-Viral Agents
Human Anti-Vegfr-2/Kdr Antibodies
Rho Kinase Inhibitors
Immunomodulatory Agents
Treatment of Brain and Central Nervous System Tumors
Treatment of Gvhd
Farnesyl Derivatives and Pharmaceutical Compositions Containing Them
Patent: 5,705,528 →
Application: 08/338,764 →
Non-Malignant Disease Treatment with Ras Antagonists
Patent: 6,462,086 →
Application: 09/597,332 →
Herbal Composition PHY906 and Its Use in Chemotheraphy
Patent: 7,025,993 →
Application: 10/220,876 →
Publication: US 2003/0211180
Treatment of Post-Angioplasty Restenosis and Atherosclerosis with Ras Antagonists
Patent: 6,946,485 →
Application: 10/420,682 →
Publication: US 2003/0203942
Receptor-Type Kinase Modulators and Methods of Use
Patent: 7,576,074 →
Application: 10/522,004 →
Publication: US 2006/0069077
Farnesyl Derivatives and Pharmaceutical Compositions Containing Them
Patent: 39,682 →
Application: 11/093,255 →
Herbal Composition PHY906 and Its Use in Chemotherapy
Patent: 7,534,455 →
Application: 11/100,433 →
Publication: US 2005/0196473
Inhibitors of Microsomal Triglyceride Transfer Protein and Apo-B Secretion
Patent: 8,980,915 →
Application: 11/407,500 →
Publication: US 2007/0027183
Antibodies That Bind Mmp-14
Patent: 7,745,587 →
Application: 11/648,423 →
Publication: US 2007/0217997
Methods and Compositions for Oral Delivery of Fts
Patent: 8,088,756 →
Application: 11/659,582 →
Publication: US 2009/0226512
Pharmacokinetically Improved Compounds
Patent: 8,357,693 →
Application: 11/887,218 →
Publication: US 2010/0144707
Treatment of Viral Infections by Modulation of Host Cell Metabolic Pathways
Patent: 8,158,677 →
Application: 12/156,517 →
Publication: US 2009/0239830
Compositions and Methods for Treating Osteolytic Disorders Comprising Mmp-14 Binding Proteins
Patent: 8,147,836 →
Application: 12/337,140 →
Publication: US 2009/0186031
Evaluating Mmp Expression in Patient Stratification and Other Therapeutic, Diagnostic and Prognostic Methods for Cancer
Patent: 8,183,008 →
Application: 12/337,218 →
Publication: US 2009/0203060
Receptor-Type Kinase Modulators and Methods of Use
Patent: 8,658,654 →
Application: 12/455,867 →
Publication: US 2009/0318373
Treatment of Lung Cancer
Patent: 8,232,253 →
Application: 12/519,578 →
Publication: US 2010/0136138
Herbal Composition PHY906 and Its Use in Chemotherapy
Patent: 8,309,141 →
Application: 12/527,302 →
Publication: US 2010/0166892
Alkoxyalkyl S-Prenylthiosalicylates for Treatment of Cancer
Patent: 8,338,481 →
Application: 12/690,174 →
Publication: US 2010/0189781
Metalloproteinase Binding Proteins
Patent: 8,106,168 →
Application: 12/776,195 →
Publication: US 2010/0266490
Use of the Combination of PHY906 and a Tyrosine Kinase Inhibitor as a Cancer Treatment Regimen
Patent: 8,871,279 →
Application: 12/997,513 →
Publication: US 2012/0009282
Rho Kinase Inhibitors
Application: 13/255,879 →
Publication: US 2012/0202793
Method for Treating Breast Cancer Using Antibody Binding to Mmp-14
Patent: 9,051,377 →
Application: 13/335,185 →
Publication: US 2012/0107231
Compositions and Methods for Treating Osteolytic Disorders Comprising Mmp-14 Binding Proteins
Patent: 8,501,181 →
Application: 13/338,622 →
Publication: US 2012/0141473
Inhibitors of Mtor Kinase as Anti-Viral Agents
Application: 13/386,547 →
Publication: US 2012/0190676
Treatment of Viral Infections by Modulation of Host Cell Metabolic Pathways
Patent: 9,029,413 →
Application: 13/438,616 →
Publication: US 2013/0065850
Treatment of Multiple Sclerosis
Application: 13/521,637 →
Publication: US 2013/0035390
Inhibitors of Long and Very Long Chain Fatty Acid Metabolism as Broad Spectrum Anti-Virals
Patent: 9,168,269 →
Application: 13/579,967 →
Publication: US 2013/0190381
Pharmacokinetically Improved Compounds
Patent: 8,853,394 →
Application: 13/708,420 →
Publication: US 2013/0096114
Pharmacokinetically Improved Compounds
Patent: 8,916,576 →
Application: 13/715,644 →
Publication: US 2013/0131047
Use of a Receptor-Type Kinase Modulator for Treating Polycystic Kidney Disease
Patent: 9,364,479 →
Application: 13/818,844 →
Publication: US 2013/0217711
Inhibitors of Mtor Kinase as Anti -Viral Agent
Application: 13/982,331 →
Publication: US 2014/0206678
Processes for the Preparation of Substituted Quinazolines
Patent: 9,359,332 →
Application: 14/060,123 →
Publication: US 2014/0155418
Combination Therapy Comprising an Mmp-14 Binding Protein
Application: 14/353,212 →
Publication: US 2014/0335082
Rho Kinase Inhibitors
Patent: 9,815,820 →
Application: 14/431,936 →
Publication: US 2015/0252025
Treatment of Ocular Disorders
Application: 14/431,948 →
Publication: US 2015/0238601
Human Anti-Vegfr-2/Kdr Antibodies
Application: 14/431,954 →
Publication: US 2015/0284464
Herbal Composition PHY906 and Its Use in Chemotherapy
Application: 14/581,610 →
Publication: US 2015/0110906
Rho-Kinase Inhibitors and Method of Preparation
Patent: 9,440,961 →
Application: 14/581,746 →
Publication: US 2015/0344464
Use of PHY906 as Treatment for Inflammatory Bowel Disease and/or Irritable Bowel Syndrome
Application: 14/605,180 →
Publication: US 2015/0182575
Inhibitors of Microsomal Triglyceride Transfer Protein and Apo-B Secretion
Patent: 9,656,960 →
Application: 14/660,453 →
Publication: US 2016/0039765
Methods and Compositions for Oral Delivery of Fts
Application: 14/662,420 →
Publication: US 2015/0191426
Treatment of Viral Infections by Modulation of Host Cell Metabolic Pathways
Application: 14/709,756 →
Methods for Treatment of Breast Cancer Nonresponsive to Trastuzumab
Patent: 9,586,940 →
Application: 14/801,335 →
Publication: US 2015/0322046
Human Anti-Vegfr-2/Kdr Antibodies
Application: 62/061,097 →
Stable Trientine Formulations
Application: 62/111,522 →
Anti-PD1 Antibodies
Application: 62/113,132 →
Glucose Uptake Inhibitors
Application: 62/185,223 →
Treatment of Infectious Diseases with Glucose Uptake Inhibitors
Application: 62/185,231 →
Related Assignments (18)
Other recorded transfers of the patents in this record — the chain of ownership.
Confirmatory License May 4, 2012
From: PRINCETON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028156/0742 →
Security Agreement Feb 7, 2013
From: KADMON CORPORATION, LLC
To: CORTLAND CAPITAL MARKET SERVICES LLC
Reel/Frame 029777/0502 →
Security Agreement Jun 25, 2013
From: KADMON CORPORATION LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030679/0116 →
Security Agreement Jun 25, 2013
From: KADMON CORPORATION LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030679/0212 →
Assignment of Assignor's Interest Jan 6, 2015
From: KIM, JI-IN; LIU, KEVIN; POYUROVSKY, MASHA; LU, DAN
To: KADMON CORPORATION, LLC
Reel/Frame 034647/0005 →
Assignment of Assignor's Interest Mar 25, 2015
From: ZHU, ZHENPING; LU, DAN
To: KADMON CORPORATION, LLC
Reel/Frame 035253/0715 →
Security Interest Aug 31, 2015
From: KADMON CORPORATION, LLC
To: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
Reel/Frame 036515/0084 →
Release of Security Interest Sep 1, 2015
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 036518/0862 →
Security Interest Sep 8, 2015
From: KADMON CORPORATION, LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 036573/0001 →
Assignment of Assignor's Interest Jun 14, 2016
From: POLONSKAYA, ZHANNA
To: KADMON CORPORATION, LLC
Reel/Frame 038907/0786 →
Nunc Pro Tunc Assignment Jul 15, 2016
From: CONCORDIA PHARMACEUTICALS, INC.
To: KADMON CORPORATION, LLC
Reel/Frame 039166/0591 →
Assignment of Assignor's Interest Jul 22, 2016
From: KADMON CORPORATION, LLC
To: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Reel/Frame 039225/0943 →
Corrective Assignment to Correct the Assignor's Name Previously Recorded at Reel: 039166 Frame: 0591. Assignor(S) Hereby Confirms the Assignment. Aug 16, 2016
From: CONCORDIA PHARMACEUTICALS, LLC
To: KADMON CORPORATION, LLC
Reel/Frame 040314/0329 →
Assignment of Assignor's Interest May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →
Merger and Change of Name Sep 10, 2021
From: SURFACE LOGIX, INC.; SURFACE LOGIX, LLC
To: SURFACE LOGIX, LLC
Reel/Frame 057468/0052 →
Release of Security Interest Oct 21, 2021
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057886/0192 →
Release of Security Interest Oct 29, 2021
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057973/0751 →
Entity Conversion Sep 17, 2025
From: SURFACE LOGIX, INC.
To: SURFACE LOGIX LLC
Reel/Frame 072915/0828 →